Aeglea Revives Fortunes By Joining Merck And Roivant In TL1A Drug Chase
Spyre Buyout Brings Potential Long-Acting Rivals To IBD Drugs
Aeglea looked to be company running out of time, but the reverse merger with Spyre Therapeutics and its TL1A-based inflammatory bowel disease assets could prove to be an inspired move.
